MoST-LLy

A clinical trial research program offering Australians with blood cancer genomic screening and potential access to precision medicines.

MoST 15 substudies 33-34: Durvalumab plus Acalabrutinib

Title: A single arm, open label, signal seeking, phase II trial of the activity of Durvalumab in combination with Acalabrutinib in patients with high-grade B cell lymphoma

The aim of this MoST-LLy substudy is to assess the clinical activity of durvalumab and acalabrutinib in patients with high grade B cell lymphoma.

Eligible Population: Adult patients with pathologically confirmed high grade B cell lymphoma enrolled in the MoST program for molecular screening are eligible for this study.

Substudy status: recruiting

ANZCTR registration number: ACTRN12621000507886


ANZCTR registration details

MoST 16 substudy 37: Pamiparib

Title: Single arm, open label, signal seeking, phase II trial of pamiparib in patients with relapsed/ refractory myeloid haematological malignancy with aberrant germline or somatic DNA repair pathway function.

The aim of this MoST-LLy substudy is to assess the clinical activity of pamiparib in patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) with germline or somatic DNA repair pathway mutation (e.g. BRCA1/2), and/or BRCA mutational signature.

Eligible Population: Adult patients with acute myeloid leukaemia or myelodysplastic syndrome who have no standard of care options or have failed these options and have enrolled in the MoST program and found to have germline or somatic DNA repair pathway mutation (e.g. BRCA1/2), and/or BRCA mutational signature.

Substudy status: recruiting

ANZCTR registration number: ACTRN12621001183875


ANZCTR registration details